Press releases appear below, filter by date.
The amended text is available on the PMCPA website
Chiesi Ltd and Vifor Pharma UK Limited have each breached the ABPI Code of Practice for the Pharmaceutical Industry and brought discredit upon, and reduced confidence in, the pharmaceutical industry. In addition, Chiesi was publicly reprimanded.
Proposals to amend the ABPI Code of Practice for the Pharmaceutical Industry were agreed at an Extraordinary General Meeting of the ABPI on Monday 11 June.
Bayer HealthCare has breached Clause 2 of the ABPI Code of Practice and is the subject of advertisements in the medical, pharmaceutical and nursing press.
Merz Pharma, Lilly and Daiichi-Sankyo have each breached the ABPI Code of Practice for the Pharmaceutical Industry and brought discredit upon, and reduced confidence in, the pharmaceutical industry.
Published updates reflect the Second 2012 Edition of the Code.Following recent changes to the ABPI Code of Practice for the Pharmaceutical Industry, the PMCPA has updated its popular e-learning module and quick guides to the Code.
Grünenthal Ltd and Vifor Pharma UK Limited have each breached Clause 2 of the ABPI Code of Practice and are the subject of advertisements in the medical, pharmaceutical and nursing press. In addition, Grünenthal has been publicly reprimanded.
Proposals to amend the ABPI Code of Practice for the Pharmaceutical Industry have been sent to companies and published on the PMCPA website.
The 2012 Code will come into effect on 1 January 2012 with a transitional period between 1 January 2012 and 30 April 2012. During this time no promotional material or activity will be regarded as being in breach of the Code if it fails to comply with its provisions only because of newly introduced requirements.
There are different transitional provisions for Clauses 17.2 and 23.8. Details are given in the supplementary information for those clauses.
Proposals to amend the ABPI Code of Practice for the Pharmaceutical Industry were agreed by the ABPI on 3 November 2011.